GLP-1 agonist medications work bymimickingthis hormone. In medication terms, anagonistis amanufacturedsubstance that attaches to a cell receptor and causes the same action as the naturally occurring substance. In other words, GLP-1 medications bind to GLP receptors to trigger the effects (or roles...
[2] Wharton, Sean et al. “Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.” The New England journal of medicine vol. 389,10 (2023): 877-888. doi:10.1056/NEJMoa2302392 [3] Wilding, John P H et al. “Onc...
[8] Merck steps into NASH space with early data for its GLP-1/glucagon receptor co-agonist. Retrieved June 14, 2023, from https://endpts.com/merck-steps-into-liver-disease-space-with-early-data-for-its-glp-1-glucagon-receptor-co-agonist/ [9] Can Novo Nordisk's blockbuster weight loss ...
[8] Merck steps into NASH space with early data for its GLP-1/glucagon receptor co-agonist. Retrieved June 14, 2023, from https://endpts.com/merck-steps-into-liver-disease-space-with-early-data-for-its-glp-1-glucagon-receptor-co-agonist/ [9] Can Novo Nordisk's blockbuster weight loss ...
coskun, t. et al. ly3298176, a novel dual gip and glp-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. mol metab. 2018, 18, 3-14. [10] frias, j. p. tirzepatide: a glucos...
[10] Frias, J. P. Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes. Expert Rev Endocrinol Metab. 2020, 15, 379-394. ...
文章导读:司美格鲁肽(Semaglutide, 最初译为索马鲁肽)由糖尿病制药巨头诺和诺德开发,是一种新型的长效胰高糖素样肽‑1受体激动剂(GLP‑1RA , glucagon‑like peptide‑1 receptor agonist),也称胰高糖素样肽‑1类似物(GLP-1类似物)。2017年12月,司美格鲁肽首次在美国FDA获批上市,2018年2月于欧盟获批...
GLP⁃１是一种由 30个氨基酸组成的肠促胰岛素激素，餐后由我们人体的回肠远端、结肠近端和迷走神经的L...
like pancreatitis or anaphylaxis, are rare. Before starting any GLP-1 agonist, discuss the medication's risks, including allergic reactions, pregnancy contraindications, and potential complications. Regular appointments with healthcare providers are necessary for monitoring the treatment's effecti...
GLP-1类药物开启新时代：实验室杂质研究保证产品质量 近日印发肥胖症诊疗指南（2024年版），重点提到减重药物的研发进展迅速，尤其是以胰高血糖素样肽-1受体激动剂（glucagon-likepeptide-1receptoragonist,GLP-1RA）为基础的新型减重药物不断问世。司美格鲁肽、利拉鲁肽、替尔泊肽等药物成为备受关注的“减肥神药”...